For media inquiries: Julie Rathbun Rathbun Communications julie@rathbuncomm.com 206-769-9219
June 21, 2024
Mozart Therapeutics Announces Oral Presentation on MTX-101 at the 2024 American Diabetes Association’s 84th Scientific Sessions
June 17, 2024
Mozart Therapeutics Doses First Cohort of Participants in Phase 1a/b Clinical Study of MTX-101, in Development for Treatment of Autoimmune Diseases
May 3, 2024
Mozart Therapeutics to Present Pre-clinical Data on KIR x ICOS CD8 Treg Modulator at Immunology 2024
More news Releases
